COVID-19 update, 21 Mar

You didn’t get your flu shot. What should you do?

I strongly urge you NOT to get the flu shot. Three reasons:

1. It is too late for this season for the flu shot. The flu season is almost over and so your chances of getting it are small. Look at this graph from the CDC website . Along the Y-axis are the number of patients who go into the hospital for influenza (the flu) per 100,000 people. The X-axis is the CDC’s version of the calendar. They start on January first with week 1 and it goes from there. So what we call Thanksgiving week, a time of food, fun, and football for the rest of us, those party animals at the CDC call ‘Week 48.’

Each different colored curve is the flu season for a given year. So you see a pattern over the years. Beginning December 1, the number of cases begins. From January 1st to about March 15th (week 10) you see the most rapid weekly increases. This is what the rest of us call ‘flu season.’ From March 15th to May 7th (week 17) the cases are tapering off as spring begins, things start to get warmer, and we spend more time outside (this virus is a vampire; show it to the sun and it explodes!).

Notice the worse flu season recently was the 2017-2018, about 50% worse than this year, when over 100,000 people were hospitalized with 61,099 flu related deaths! I bet you didn’t hear about that then, did you?

Back to the present. The flu season for 2019-20 is that incomplete red line (news flash; the CDC cannot predict the future and so the line stops with this week) is literally over with less than 10% of the cases left in the season.

2. Exposure to COVID-19 in medical facilities. You have to go to the pharmacy, local clinic, doctor’s office, or hospital to get a flu shot. These are exactly the locations where all the cOVID-19 patients are going when symptoms begin. A US-educated physician colleague of mine living in Shanghai says the medical community rumor there is that it takes 15 seconds in a room with a COVID-19 patient to become infected.

3. Free up non-essential medical resources. As a community we need to allow the medical community to focus on this pandemic for the next few weeks or months while it is still growing so fast. So all elective procedures, routine check-ups, wellness evaluations, etc. should be postponed until this crisis resolves.

This data can be found here: https://www.cdc.gov/flu/weekly/#S2

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer